NexMed, Inc. 

(Public, NASDAQ:NEXM)   Watch this stock   
Find more results for NEXM
Nov 10, 2009
Q3 2009 Conference Call
Nov 9, 2009
Q3 2009 Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -1081.82% -86.82%
Operating margin -830.91% -86.87%
EBITD margin - -78.71%
Return on average assets -64.95% -53.79%
Return on average equity -286.41% -163.23%
Employees 13 -

Address

89 Twin Rivers Drive
East Windsor, NJ 08520
United States - Map
+1-609-3718123 (Phone)
+1-609-2081868 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

NexMed, Inc. discussions

  View all discussions »

Description

NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity.

Officers and directors

Richard J. Berman
Chairman of the Board
Age: 66
Bio & Compensation - Reuters
Vivian H. Liu
President, Chief Executive Officer, Secretary, Director
Age: 47
Bio & Compensation - Reuters
Mark Westgate
Chief Financial Officer, Vice President, Treasurer
Age: 39
Bio & Compensation - Reuters
Martin R. Wade III
Director
Age: 60
Bio & Compensation - Reuters
Arthur D. Emil Esq.
Director
Age: 84
Bio & Compensation - Reuters
Leonard A. Oppenheim
Director
Age: 62
Bio & Compensation - Reuters
David S. Tierney M.D.
Director
Age: 46
Bio & Compensation - Reuters